Department for NMR-based Structural Biology, Max Planck Institute for Biophysical Chemistry, 37077 Göttingen, Germany.
J Am Chem Soc. 2013 Feb 20;135(7):2853-62. doi: 10.1021/ja312471h. Epub 2013 Feb 5.
Antiaggregation drugs play an important role in therapeutic approaches for Alzheimer's disease. Although a large number of small molecules that inhibit the aggregation of the tau protein have been identified, little is known about their mode of action. Here, we reveal the mechanism and the nature of tau species that are generated by interaction of tau with the organic compound pthalocyanine tetrasulfonate (PcTS). We demonstrate that PcTS interferes with tau filament formation by targeting the protein into soluble oligomers. A combination of NMR spectroscopy, electron paramagnetic resonance, and small-angle X-ray scattering reveals that the soluble tau oligomers contain a dynamic, noncooperatively stabilized core with a diameter of 30-40 nm that is distinct from the core of tau filaments. Our results suggest that specific modulation of the conformation of tau is a viable strategy for reduction of pathogenic tau deposits.
抗聚集药物在阿尔茨海默病的治疗方法中发挥着重要作用。尽管已经鉴定出大量抑制 tau 蛋白聚集的小分子,但对其作用机制知之甚少。在这里,我们揭示了 tau 蛋白与有机化合物酞菁四磺酸钠(PcTS)相互作用所产生的 tau 物种的机制和性质。我们证明 PcTS 通过将蛋白质靶向可溶性低聚物来干扰 tau 纤维的形成。NMR 光谱、电子顺磁共振和小角 X 射线散射的组合表明,可溶性 tau 低聚物含有一个直径为 30-40nm 的动态、非合作稳定核心,与 tau 纤维的核心不同。我们的结果表明,tau 构象的特异性调节是减少致病 tau 沉积的可行策略。